A5005048121- Metabolism, Diabetes, and Cancer
- Bone Metabolism and Diseases
- Bone health and osteoporosis research
- Advanced Glycation End Products research
- Bone health and treatments
- Diet and metabolism studies
- Clinical practice guidelines implementation
- Liver Disease Diagnosis and Treatment
- Metabolism and Genetic Disorders
- Meta-analysis and systematic reviews
- Neuroscience of respiration and sleep
- Natural Antidiabetic Agents Studies
- Adrenal and Paraganglionic Tumors
- Pituitary Gland Disorders and Treatments
- Hormonal and reproductive studies
- TGF-β signaling in diseases
- Health and Medical Education
- Diet, Metabolism, and Disease
- NF-κB Signaling Pathways
- Body Composition Measurement Techniques
- Adrenal Hormones and Disorders
- Hormonal Regulation and Hypertension
- S100 Proteins and Annexins
- Vitamin K Research Studies
- Aldose Reductase and Taurine
Universidad Nacional de La Plata
2006-2025
Hospital César Milstein
1996-2008
Abstract Diabetes mellitus is associated with bone loss. Patients type 2 diabetes are frequently treated oral antidiabetic drugs such as sulfonylureas, biguanides, and thiazolidinediones. Rosiglitazone treatment has been shown to increase adipogenesis in marrow induce In this study we evaluated the effect of vivo vitro metformin on progenitor cells (BMPCs), well involvement AMPK pathway its effects. The coincubation rosiglitazone adipogenic differentiation BMPCs also was studied. addition,...
Advanced glycation endproducts (AGEs) are implicated in the complications of diabetes and ageing, affecting several tissues, including bone. Metformin, an insulin-sensitizer drug, reduces risk life-threatening macrovascular complications. We have evaluated hypothesis that metformin can abrogate AGE-induced deleterious effects osteoblastic cells culture. In two osteoblast-like cell lines (UMR106 MC3T3E1), AGE-modified albumin induced death, caspase-3 activity, altered intracellular oxidative...
Metabolic syndrome (MetS) is associated with osteogenic transdifferentiation of vascular smooth muscle cells (VSMC) and accumulation arterial calcifications (AC). Metformin (MET) inhibits this in vitro. Here, we evaluate the vivo efficacy oral MET to reduce AC a model MetS. 20 young male Wistar rats were divided into 2 groups: one received water, other water plus 20% fructose induce After 14 days, for another 4 weeks, (100 mg/kg/day) was added half each group’s drinking source, thus: C...
Cytokines and nitric oxide (NO) have been implicated in bone loss caused by estrogen deficiency. Here we evaluated the effect of synthase (NOS) inhibitors on particle resorbing activity TNF-α release cultured peripheral blood monocytes (PBM) obtained from 10 premenopausal (PreM) postmenopausal (PostM) women. Gonadal status (menopause < 3 yr) was assessed FSH estradiol. Bone alkaline phosphatase N-Telopeptide were significantly increased PostM. Significant differences between PreM PostM women...
Motivation for the study. Most research supports a negative association between metabolic syndrome and bone health, although there is an overall lack of consensus. Therefore, need in this area to develop better understanding. Main findings. Metabolic induced by fructose-rich diet increases adipogenic predisposition marrow progenitor cells femoral medullary adiposity rats. Furthermore, can be partially prevented co-treatment with metformin. Implications. Experimental has effects on tissue...